The synergistic in vivo tumor-suppressive efficacy of C/M@Alb NCs was evaluated against HT-29 subcutaneous tumors using 3 doses of injections, and the tumor volume was monitored for 21 d (Fig. 4A). This evidence concerns the gene ALB and neoplasm.